[Klotho and vascular calcification]

Area of Science:

• Nephrology
• Cardiology
• Vascular Biology

Background:

• The cardiorenal connection between chronic kidney disease (CKD) and cardiovascular diseases is a growing area of research.
• Vascular calcification, linked to reduced Klotho protein, plays a role in cardiorenal syndrome.
• Klotho protein levels decrease with declining kidney function, even in early stages of CKD.

Purpose of the Study:

• To elucidate the role of Klotho protein in the pathogenesis of vascular calcification within the context of cardiorenal connections.
• To understand how Klotho's expression and function are altered in CKD and impact vascular health.

Main Methods:

• The study discusses the correlation between Klotho expression and estimated glomerular filtration rate (eGFR).
• It examines the role of fibroblast growth factor 23 (FGF23) in early CKD compensatory mechanisms.
• It investigates the mechanism by which Klotho down-regulation in advanced CKD promotes vascular smooth muscle cell (VSMC) calcification.

Main Results:

• Klotho expression is reduced in patients with eGFR between 60-90 mL/min/1.73 m2 compared to those with eGFR >90.
• In end-stage kidney disease, impaired Klotho function leads to phosphate retention and VSMC osteochondrocytic differentiation.
• Klotho expressed in VSMCs inhibits their differentiation and phosphate uptake, thus preventing vascular calcification.

Conclusions:

• Both renal and vascular Klotho are crucial in protecting vascular smooth muscle cells against calcification.
• Down-regulation of Klotho in CKD is a key factor in the development of vascular calcification and cardiorenal complications.
• Maintaining Klotho levels may be a therapeutic target for managing cardiorenal syndrome.